A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer
Phase 1
Terminated
- Conditions
- Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment
- Interventions
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Precirix
- Target Recruit Count
- 13
- Registration Number
- NCT04467515
- Locations
- 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
🇨🇦Princess Margaret Hospital, Toronto, Ontario, Canada
Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Tumor Imaging Potential of [131I]-SGMIB Anti-HER2 VHH1 in Healthy Volunteers and Breast Cancer Patients
Phase 1
Completed
- Conditions
- Healthy VolunteersBreast Cancer
- Interventions
- Biological: [131I]-SGMIB Anti-HER2 VHH1
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Precirix
- Target Recruit Count
- 9
- Registration Number
- NCT02683083
- Locations
- 🇧🇪
UZ Brussel, Brussels, Choose A State, Belgium
© Copyright 2025. All Rights Reserved by MedPath